Ramucirumab Injection

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Tianjin Medical University Cancer Institute and Hospital

Conditions

Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyColo-rectal CancerGastric CancerNon-small Cell Lung Cancer

Phase 1

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

CompletedNCT05800418

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Colo-rectal Cancer, Gastric Cancer, Non-small Cell Lung Cancer

Start: 2019-11-04End: 2020-02-18Updated: 2023-04-05

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Tianjin Medical University Cancer Institute and HospitalAdvanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Start: 2024-06-01End: 2025-05-01Target: 30Updated: 2024-04-15